New Immune-Boosting drug combo targets Hard-to-Treat cancers

NCT ID NCT06413680

Recruiting now Disease control Sponsor: Regeneron Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests an experimental drug called REGN10597, alone or with another drug (cemiplimab), in people with advanced solid tumors like melanoma and kidney cancer. The goal is to see if the treatment is safe and can shrink tumors. About 240 participants will receive the drug in different doses to find the best balance of safety and effectiveness.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: REGN10597 (a fusion protein that targets PD-1 and IL-2 receptors) and cemiplimab (an immunotherapy drug)
What this could lead to: If successful, this could lead to a new treatment option for people with advanced solid tumors like melanoma and kidney cancer that have stopped responding to standard therapies.
What could go wrong: This is an early-phase trial (Phase 1/2a) with a small number of participants, so the drug may not prove effective or safe enough for wider use. Side effects from the immune system are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

melanoma neoplasm Neoplasm Metastasis nonpapillary renal cell carcinoma renal cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMORS CLEAR CELL RENAL CELL CARCINOMA (CCRCC) MELANOMA

Contacts and locations

Locations

MD Anderson Cancer Center
RECRUITING

Houston, Texas, 77030, United States
Next Oncology
RECRUITING

San Antonio, Texas, 78229, United States
Northwell Health
RECRUITING

Lake Success, New York, 11042, United States
Start Midwest Cancer Research
RECRUITING

Grand Rapids, Michigan, 49546, United States
The Start Center for Cancer Care
RECRUITING

San Antonio, Texas, 78229, United States
USC Norris Comprehensive Cancer Center
RECRUITING

Los Angeles, California, 90089, United States
University of California San Francisco (UCSF)
RECRUITING

San Francisco, California, 94143, United States
University of Chicago
RECRUITING

Chicago, Illinois, 60637, United States
University of North Carolina at Chapel Hill
RECRUITING

Chapel Hill, North Carolina, 27514, United States
University of Pittsburgh Medical Center - Hillman Cancer Center
RECRUITING

Pittsburgh, Pennsylvania, 15232, United States
Yale School of Medicine
RECRUITING

North Haven, Connecticut, 06473, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.